Dermata Therapeutics, Inc.
DRMADermata Therapeutics, Inc. in brief
Dermata Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. It was founded in 2014. Its market value was $4 M on 30 October 2026, which makes it the 27,094th largest listed company in the world and the 4,429th largest in the USA on this site. Gerald T. Proehl is its chief executive. Its shares trade under the symbol DRMA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Dermata Therapeutics, Inc.
We are a scientific leader in skincare, dedicated to the development and commercialization of products that address common and underserved skin conditions. Dermata initially was founded with a focus on researching and developing prescription products subject to the FDA approval process. As part of this focus, we had one lead asset, referred to as XYNGARI, also known as DMT310, which we had been studying in clinical trials for the treatment of moderate-to-severe acne. In March 2025, we announced that we achieved statistically significant results from our Phase 3 STAR-1 clinical trial of XYNGARI, formerly our lead prescription candidate incorporating our Spongilla lacustris for moderate-to-severe acne. XYNGARI demonstrated statistically significant results across all three co-primary endpoints at weeks 4, 8, and 12 when compared with placebo. Following the successful completion of the STAR-1 trial, we conducted a full assessment of the Rx acne landscape and the future Rx acne development pathway for XYNGARI. In September 2025, after an extensive review of current trends in dermatology, changing consumer preferences, additional non-clinical and clinical development costs, and go-to market costs for an Rx acne product, management, with support from our board of directors, determined that a strategic shift to developing and distributing DTC and B2B skincare products, that are backed by science, would be a better path to commercialization with potentially greater financial upside and faster time to market. We believe we can leverage our history and knowledge of Rx dermatology to create skincare products that are effective and safe, and available to consumers without the nuisance of obtaining a prescription. We believe this strategic repositioning will accelerate our path to commercialization, reduce our regulatory burden, and decrease development expenses, all while enabling us to address broad consumer segments in the skincare market.
From the company's annual report filed with the US SEC: read the report
Dermata Therapeutics, Inc. timeline
- 2014
- 🏁· approximateFounded
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 16 August 2021; shares registered for exchange trading on 11 August 2021.
Events of Dermata Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,561 (Jan 2022) · #5,891 (Dec 2022) · #4,726 (Jan 2024) · #2,455 (Mar 2026) · #4,099 (Aug 2026) · #4,345 (Oct 2026) · #4,431 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.7×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -121.5%
- Liabilities / assets
- 20.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-8M | $-8M | — |
| Dec 2024 | — | — | $-13M | $-12M | — |
| Dec 2023 | — | — | $-8M | $-8M | — |
| Dec 2022 | — | — | $-10M | $-10M | — |
| Dec 2021 | — | — | $-8M | $-8M | — |
| Dec 2020 | — | — | $-3M | $-3M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | — | — | $-8.16 | — |
| Dec 2024 | $-11M | — | — | $-80.32 | — |
| Dec 2023 | $-6M | — | — | $-39.99 | — |
| Dec 2022 | $-9M | — | — | — | — |
| Dec 2021 | $-6M | — | — | — | — |
| Dec 2020 | $-4M | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportOther events
- Aug 17, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Aug 5, 20268-KCurrent reportOther events
- May 27, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 17, 2026DEF 14AProxy statement
- Mar 26, 202610-KAnnual report · period to Dec 2025
Official filings of Dermata Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-8 M
- Net income
- $-8 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $2 M
- Total equity
- $6 M
As of December-2025
Top 15 institutional investors in Dermata Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors LLC | 32,796 | New | 0.67% | $0 M | Nov 16, 2026 |
| 2 | Geode Capital Management, LLC | 20,101 | -102 (-0.50%) | 0.41% | $0 M | Nov 6, 2026 |
| 3 | Welch & Forbes LLC | 20,000 | 0 (0.00%) | 0.41% | $0 M | Nov 4, 2026 |
| 4 | HRT Financial LP | 19,403 | New | 0.39% | $0 M | Nov 13, 2026 |
| 5 | State Street Corp | 18,747 | 0 (0.00%) | 0.38% | $0 M | Nov 12, 2026 |
| 6 | UBS Group AG | 17,115 | +319 (+1.90%) | 0.35% | $0 M | Nov 10, 2026 |
| 7 | Jane Street Group, LLC | 16,589 | New | 0.34% | $0 M | Nov 12, 2026 |
| 8 | XTX Topco Ltd | 12,877 | -1,910 (-12.92%) | 0.26% | $0 M | Nov 16, 2026 |
| 9 | Citigroup Inc | 6,625 | New | 0.13% | $0 M | Nov 4, 2026 |
| 10 | Vanguard Capital Management LLC | 5,438 | New | 0.11% | $0 M | Nov 13, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 313 | -3,547 (-91.89%) | 0.01% | $0 M | Nov 16, 2026 |
| 12 | SBI Securities Co., Ltd. | 102 | +1 (+0.99%) | 0.00% | $0 M | Oct 22, 2026 |
| 13 | Highline Wealth Partners LLC | 26 | 0 (0.00%) | 0.00% | $0 M | Oct 19, 2026 |
| 14 | Jpmorgan Chase & Co | 3 | New | 0.00% | $0 M | Nov 12, 2026 |
| 15 | Morgan Stanley | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Dermata Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 41,321 | $0 M | 0.84% | <0.01% | +92% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,106 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Dermata Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gerald T. ProehlPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Grant or awardindirect | +170,068 | — | — | 292,631 | Form 4 |
| filed | Kyri K. Van HooseSVP, CFO | Grant or award | +102,040 | — | — | 232,463 | Form 4 |
| filed | Kathleen D. ScottDirector | Sell | -11 | $1.190 | $13 | 0 | Form 4 |
| filed | Munera Maria E. Bedoya-ToroSVP, Regulatory Affairs | Buy | +1,000 | $1.270 | $1 K | 1,012 | Form 4 |
| filed | Kyri K. Van HooseSVP, CFO | Grant or award | +122,549 | — | — | 130,423 | Form 4 |
| filed | Gerald T. ProehlPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Grant or awardindirect | +490,196 | — | — | 490,255 | Form 4 |
| filed | Gerald T. ProehlPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Grant or awardindirect | +122,549 | — | — | 122,563 | Form 4 |
| filed | David F. HaleDirector | Grant or awardindirect | +78,741 | — | — | 80,957 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Dermata Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-15 14:26 UTC, code LUDP, resumed 14:31 UTC
- 2025-07-31 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-03-27 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 20,379 shares at $0.84
- : 23,543 shares at $0.87
- : 2,345 shares at $0.72
- : 382 shares at $0.86
- : 57 shares at $0.80
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Dermata Therapeutics, Inc. scorecard#
Passes 1 of the 9 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-8.16 vs -80.32Diluted EPS -8.16 in fiscal 2025 against -80.32 the year before (report's currency).
- ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$3 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-194.3%-194.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Dermata Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 2,930−64.3%— | 8,204+102%— | 4,070−28.0%— | 5,651+63.4%— | 3,459+115%— | 1,608—— | |
| Selling, general and administrative | 4,844+12.4%— | 4,310—— | — | — | — | — | |
| General and administrative | — | 4,310+8.5%— | 3,972−1.3%— | 4,023−8.5%— | 4,398+181%— | 1,565—— | |
| Operating expenses | 7,774−37.9%— | 12,513+55.6%— | 8,042−16.9%— | 9,674—— | — | — | |
| Operating income | −7,774—— | −12,513—— | −8,042—— | −9,674—— | −7,857—— | −3,173—— | |
| Interest and finance income | 215−4.8%— | 226—— | — | — | — | — | |
| Interest expense and finance costs | — | — | — | — | 46−76.9%— | 197—— | |
| Net interest income | — | — | — | 64—— | −46—— | — | |
| Income tax | — | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | — | −12,287—— | −7,795—— | — | — | — | |
| Net income attributable to shareholders | −7,559—— | −12,287—— | −7,795—— | −9,611—— | −7,902—— | −3,237—— | |
| Earnings per share, basic | -8.16—— | -80.32r-8.03—— | -39.99r-2.67—— | -13.92r-0.87—— | -2.43—— | -1.69—— | |
| Earnings per share, diluted | -8.16—— | -80.32r-8.03—— | -39.99—— | — | — | — | |
| Shares, weighted average (basic) | 0.9+505%— | 0.2—— | — | — | 4.3+125%— | 1.9—— | |
| Shares, weighted average (diluted) | 0.9+505%— | 0.2r1.5−21.5%— | 0.2—— | — | — | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 7,522+138%95.7% | 3,162−57.5%89.5% | 7,438+19.2%93.2% | 6,241−42.2%89.9% | 10,799+1936%92.9% | 530—87.6% | |
| Other current assets | 342−8.2%4.3% | 372−31.1%10.5% | 540−23.1%6.8% | 703−14.8%10.1% | 825+999%7.1% | 75—12.4% | |
| Current assets | 7,864—100% | — | — | — | 11,624+1820%100% | 605—100% | |
| Property, plant and equipment | — | — | — | — | 0—0.0% | 0—0.0% | |
| Total assets | 7,864+123%100% | 3,534−55.7%100% | 7,979+14.9%100% | 6,944−40.3%100% | 11,624+1820%100% | 605—100% | |
| Accounts payable | 461−43.0%5.9% | 808−6.7%22.9% | 866+74.4%10.9% | 497−3.6%7.2% | 515+394%4.4% | 104—17.2% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 556—91.9% | |
| Current liabilities | — | — | — | — | 1,517−59.9%13.0% | 3,783—625% | |
| Total liabilities | 1,640−16.8%20.9% | 1,973+21.5%55.8% | 1,624+76.0%20.3% | 923−39.2%13.3% | 1,517−59.9%13.0% | 3,783—625% | |
| Retained earnings | −73,234—−931% | −65,675—−1858% | −53,388—−669% | −45,593—−657% | −35,982—−310% | −28,080—−4638% | |
| Shareholders' equity | 6,223+299%79.1% | 1,561−75.4%44.2% | 6,355+5.5%79.7% | 6,022−40.4%86.7% | 10,107—87.0% | −3,178—−525% | |
| Total liabilities and equity | 7,864+123%100% | 3,534−55.7%100% | 7,979+14.9%100% | 6,944−40.3%100% | 11,624+1820%100% | 605—100% | |
| Shares outstanding | 2.7+957%— | 0.3r2.5−3.9%— | 0.3r3.9−66.0%— | 0.8r12−90.8%— | 8.3—— | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | — | — | — | — | 0−100%— | 0.3—— | |
| Share-based compensation | 144−78.1%— | 658+26.0%— | 522−43.9%— | 930−51.2%— | 1,905—— | 0—— | |
| Cash from operating activities | −7,758—— | −11,163—— | −6,409—— | −8,834—— | −5,693—— | −4,029—— | |
| Shares issued | 12,168+76.7%— | 6,886−9.5%— | 7,606+77.9%— | 4,276−72.2%— | 15,386—— | — | |
| Cash from financing activities | 12,118+76.0%— | 6,886−9.5%— | 7,606+77.8%— | 4,277−73.2%— | 15,962+522%— | 2,567—— | |
| Change in cash | 4,360—— | −4,277—— | — | — | 10,268—— | −1,461—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 74—100% | — | — | — | — | — | — | — | — | — | — | — | |
| Cost of revenue | — | 34—45.9% | — | — | — | — | — | — | — | — | — | — | — | |
| Gross profit | — | 40—54.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Research and development | 1,266−72.4%— | 143−71.6%193% | 213−65.6%— | 384−70.0%— | 527*−76.0%— | 504−79.0%— | 618−69.2%— | 1,281−20.0%— | 2,192*+93.1%— | 2,401—— | 2,009—— | 1,601—— | 1,135*—— | |
| Selling, general and administrative | 8,473+89.2%— | 2,755+119%3717% | 2,801+143%— | 1,543+45.7%— | 1,374*+36.3%— | 1,256+52.4%— | 1,155—— | 1,059—— | 1,008*—— | 824—— | — | — | — | |
| General and administrative | — | — | — | — | — | — | 1,155+32.0%— | 1,059−33.9%— | 1,008*−7.1%— | 824—— | 875—— | 1,603—— | 1,085*—— | |
| Operating expenses | 9,739+7.3%— | 2,899+64.6%3910% | 3,014+70.0%— | 1,926−17.7%— | 1,900*−40.6%— | 1,761−45.4%— | 1,773−38.5%— | 2,340−27.0%— | 3,200*+44.2%— | 3,226—— | 2,884—— | 3,204—— | 2,220*—— | |
| Operating income | −9,699—— | −2,858—−3856% | −3,014—— | −1,926—— | −1,900*—— | −1,761—— | −1,773—— | −2,340—— | −3,200*—— | −3,226—— | −2,884—— | −3,204—— | −2,220*—— | |
| Interest and finance income | 201−11.1%— | 37−46.0%50.0% | 47−35.1%— | 79+117%— | 39*−22.0%— | 69+30.8%— | 72+31.1%— | 36−47.7%— | 49*—— | 52—— | 55—— | 69—— | — | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −3,151*—— | −3,173*—— | −9,098*—— | 3,134—— | −2,134*—— | |
| Net income attributable to shareholders | −9,498—— | −2,821—−3806% | −2,967—— | −1,848—— | −1,862*—— | −1,692—— | −1,701—— | −2,304—— | −3,151*—— | −3,173—— | −2,829—— | −3,134—— | −2,134*—— | |
| Earnings per share, basic | — | -0.55—— | -0.74—— | -0.48—— | — | -1.65—— | -1.22r-1.66—— | -4.47r-0.45—— | — | -20.41—— | -41.82—— | -7.06—— | — | |
| Earnings per share, diluted | — | -0.55—— | -0.74—— | -0.48—— | — | -1.65—— | -1.66—— | -4.47r-0.45—— | — | -20.41—— | -41.82—— | -7.06—— | — | |
| Shares, weighted average (basic) | 5.1+399%— | 5.1+399%— | 4.0+292%— | 3.9+649%— | — | 1.0+560%— | 1.0+1417%— | 0.5r5.2+16.1%— | — | 0.2—— | 0.1—— | 0.4—— | — | |
| Shares, weighted average (diluted) | 5.1+399%— | 5.1+399%— | 4.0+292%— | 3.9+649%— | — | 1.0+560%— | 1.0+1417%— | 0.5r5.2+16.1%— | — | 0.2—— | 0.1—— | 0.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4,822—72.7% | 4,822+3.4%72.7% | 4,413−31.9%82.9% | 6,945−28.5%93.0% | 7,522+138%95.7% | 4,664−24.1%92.0% | 6,481+31.0%97.6% | 9,719+105%97.1% | 3,162−57.5%89.5% | 6,144—91.9% | 4,947—94.5% | 4,734—91.4% | 7,438—93.2% | |
| Inventory | 825—12.4% | 825—12.4% | 150—2.8% | 93—1.2% | — | — | — | — | — | — | — | — | — | |
| Other current assets | 583—8.8% | 583+43.2%8.8% | 594+272%11.2% | 427+49.5%5.7% | 342−8.2%4.3% | 407−25.1%8.0% | 160−44.9%2.4% | 286−35.9%2.9% | 372−31.1%10.5% | 544—8.1% | 289—5.5% | 446—8.6% | 540—6.8% | |
| Current assets | 6,431—96.9% | 6,431—96.9% | 5,156—96.9% | — | 7,864—100% | — | — | — | — | — | — | — | — | |
| Property, plant and equipment | 159—2.4% | 159—2.4% | 129—2.4% | — | — | — | — | — | — | — | — | — | — | |
| Total assets | 6,635—100% | 6,635+30.8%100% | 5,321−19.9%100% | 7,466−25.4%100% | 7,864+123%100% | 5,071−24.2%100% | 6,641+26.8%100% | 10,005+93.2%100% | 3,534−55.7%100% | 6,687—100% | 5,237—100% | 5,180—100% | 7,979—100% | |
| Accounts payable | 1,620—24.4% | 1,620+257%24.4% | 1,120+171%21.0% | 318−77.2%4.3% | 461−43.0%5.9% | 453−47.5%8.9% | 414−68.8%6.2% | 1,395+69.6%13.9% | 808−6.7%22.9% | 864—12.9% | 1,327—25.3% | 823—15.9% | 866—10.9% | |
| Total liabilities | 2,730—41.1% | 2,730+146%41.1% | 1,833+78.6%34.5% | 1,053−61.1%14.1% | 1,640−16.8%20.9% | 1,111−42.9%21.9% | 1,026−46.5%15.5% | 2,704+97.1%27.0% | 1,973+21.5%55.8% | 1,946—29.1% | 1,918—36.6% | 1,372—26.5% | 1,624—20.3% | |
| Retained earnings | −80,870—−1219% | −80,870—−1219% | −78,049—−1467% | −75,082—−1006% | −73,234—−931% | −71,372—−1407% | −69,680—−1049% | −67,979—−679% | −65,675—−1858% | −62,524—−935% | −59,351—−1133% | −56,522—−1091% | −53,388—−669% | |
| Shareholders' equity | 3,906—58.9% | 3,906−1.4%58.9% | 3,488−37.9%65.5% | 6,413−12.2%85.9% | 6,223+299%79.1% | 3,960−16.5%78.1% | 5,614+69.2%84.5% | 7,301+91.7%73.0% | 1,561−75.4%44.2% | 4,741—70.9% | 3,318—63.4% | 3,808—73.5% | 6,355—79.7% | |
| Total liabilities and equity | 6,635—100% | 6,635+30.8%100% | 5,321−19.9%100% | 7,466−25.4%100% | 7,864+123%100% | 5,071−24.2%100% | 6,641+26.8%100% | 10,005+93.2%100% | 3,534−55.7%100% | 6,687—100% | 5,237—100% | 5,180—100% | 7,979—100% | |
| Shares outstanding | 4.9—— | 4.9+484%— | 4.0+531%— | 4.0−33.3%— | 2.7+957%— | 0.8−49.7%— | 0.6−8.0%— | 6.0−9.4%— | 0.3r2.5−3.9%— | 1.7—— | 0.7—— | 6.7—— | 0.3r3.9—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 157+8.8%— | 42+11.5%56.9% | 42+6.5%— | 43+16.4%— | 29*−1.2%— | 38+80.3%— | 39+100%— | 37−93.7%— | 30*−76.8%— | 21—— | 20—— | 587—— | 128*—— | |
| Cash from operating activities | −8,880—— | −2,650*—−3574% | −2,422*—— | −2,480—— | −1,329*—— | −1,804*—— | −2,690*—— | −1,934—— | −2,914*—— | −3,419*—— | −2,126*—— | −2,704—— | −1,147*—— | |
| Capital expenditure | — | −53*—−71.5% | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | — | −53*—−71.5% | — | — | — | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | 4,187*—— | −13*−100%— | −548*−123%— | 8,541—— | −70*−104%— | 4,545*—— | 2,410*—— | 0—— | 1,954*—— | |
| Cash from financing activities | 9,402+19.6%— | 3,312*—4468% | −0.3*—— | 1,903−77.6%— | 4,187*—— | −13*−100%— | −548*−123%— | 8,492—— | −69*−104%— | 4,616*—— | 2,339*—— | 0—— | 1,954*—— | |
| Change in cash | 358—— | 610*—822% | −2,533*—— | −577−109%— | 2,858*—— | −1,817*−252%— | −3,238*−1617%— | 6,558—— | −2,982*—— | 1,197*—— | 213*—— | −2,704—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Dermata Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Auditor changed 2 · Directors and officers 2 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Auditor changed | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleShareholder rights changed | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2025 | $4 M | Private placement after listing | $2 to $10 million | 14 | equity, options | SEC |
| Jan 2025 | $3 M | Private placement after listing | $2 to $10 million | 8 | equity, options | SEC |
| Sep 2024 | $4 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Dermata Therapeutics, Inc. compares in Biotechnology
- Market cap$4 M · higher than 4% of 726
- Price / book0.7× · lower than 86% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Dermata Therapeutics, Inc.🇺🇸 | $4 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Dermata Therapeutics, Inc.? Verify and update this profile — free
Show Dermata Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.